Coronado Biosciences (CNDO) Announces IND Submission For TSO For The Treatment Of Moderate To Severe Chronic Plaque Psoriasis
12/9/2013 9:32:41 AM
BURLINGTON, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a Phase 2 clinical study of Trichuris suis ova (TSO) for the treatment of moderate to severe chronic plaque psoriasis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by